Results 191 to 200 of about 52,225 (202)

Detection of bcr/abl fusion transcripts by semiquantitative multiplex RT-PCR combined with a colormetric assay in Ph positive leukemia

Cancer Letters, 1998
Shinsuke Harada, Kazuya Tsuboi, Shogo Banno   +2 more
exaly  

Imatinib for relapsed BCR/ABL positive leukemias.

Annals of hematology, 2003
O G, Ottmann, B, Wassmann, D, Hoelzer
openaire   +1 more source

Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.

Gene, 2014
D. Joshi, S. Chandrakala, S. Korgaonkar, K. Ghosh, B. Vundinti   +4 more
semanticscholar   +1 more source

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

Cancer, 2005
Hagop Kantarjian, Ralph B Arlinghaus, Jorge Cortes   +2 more
exaly  

BCR/ABL Oncoprotein-Targeted Antitumor Activity of Antisense Oligodeoxynucleotides Complementary to BCR/ABL mRNA and Herbimycin A, an Antagonist of Protein Tyrosine Kinase: Inhibitory Effects on In Vitro Growth of Ph1-Positive Leukemia Cells and BCR/ABL Oncoprotein-Associated Transformed Cells

Leukemia and Lymphoma, 1993
Mihiro Okabe, Takuto Miyagishima, Masanobu Kobayashi   +2 more
exaly  

Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR–ABL-positive cells

Oncogene, 2013
Nicolas Chatain, P. Ziegler, D. Fahrenkamp, E. Jost, R. Moriggl, H. S. D. Leur, G. Müller-Newen   +6 more
semanticscholar   +1 more source

Jak2 is involved in c-Myc induction by Bcr-Abl

Oncogene, 2002
Shanhai Xie, Ralph B Arlinghaus, Arlinghaus Ralph B   +2 more
exaly  

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review

Leukemia Research, 2010
Xin An, Amit K Tiwari, Yibo Sun
exaly  

Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo

Cancer Letters, 2018
Akinobu Ota, Sivasundaram Karnan, Ichiro Hanamura   +2 more
exaly  

Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL

Leukemia, 2009
exaly